A
Alcista
Alcista · 25%PBM
$4.72
Precio del escenario
$3.055
+0.119 (+3.91%)Al cierre
Loading chart…
- Máximo
- 3.140
- Apertura
- 3.020
- Precio medio ponderado por volumen
- 3.05
- Volumen
- 24.52K
- Capitalización
- —
- Mínimo
- 2.950
- Importe
- 74.75K
- EV/EBITDA, TTM
- 0.00
Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. The Company is focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine. The Company is engaged in addressing unmet mental health needs. It is also focused on an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.
Análisis de IA of Psyence Biomedical Ltd (PBM)
MantenerPsyence Biomedical Ltd is not a good buy right now due to its current price of 3.06, which is significantly down 90.21% year-to-date. The RSI is at 28.64, indicating that the stock is oversold, but the forward P/E ratio is 0, suggesting a lack of earnings growth potential. The main risk is the company's high volatility, with a 52-week change of -96.83%.
Métricas de valoración
El PER previsto actual de Psyence Biomedical Ltd (PBM) es 0.00, frente a su media de 5 años de 0.00.
Escenarios de precio de Alphio AI para PBM
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
7.509-28NASDAQ.COMPsyence Biomedical Secures Exclusive Ibogaine Development Deal
8.509-23NASDAQ.COMPsyence BioMed Commits $5 Million to Support U.S. Ibogaine Program
8.509-14NASDAQ.COMPsyence Establishes Texas Ibogaine Research Corporation for U.S. Development
8.508-19NASDAQ.COMPsyence Biomedical Welcomes U.S. Support for Ibogaine Development
8.508-18NewsfilterPsyence BioMed Welcomes Trump's Support for Accelerated Ibogaine Development
Preguntas frecuentes sobre PBM, respondidas por Alphio AI
Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. The Company is focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine. The Company is engaged in addressing unmet mental health needs. It is also focused on an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Psyence Biomedical Ltd is not a good buy right now due to its current price of 3.06, which is significantly down 90.21% year-to-date. The RSI is at 28.64, indicating that the stock is oversold, but the forward P/E ratio is 0, suggesting a lack of earnings growth potential. The main risk is the company's high volatility, with a 52-week change of -96.83%.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.